

24 March 2021

Our Ref: RFI 37749

Dear

**Freedom of Information Act 2000
Information in Relation to Lung Cancer Treatments**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 10 February 2021.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Joyce Batch
Information Governance Officer

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

A1. The number of Urothelial cancer patients who were treated by the Trust with the drugs specified is provided in Table 1 below;

Table 1

Drug	Number of Patients
Atezolizumab	<5*
Carboplatin with Gemcitabine	<5*
Carboplatin with Paclitaxel	0
Carboplatin single or in any other combination	0
Cisplatin with Gemcitabine	0
Cisplatin single or in any other combination	0
Nivolumab	0
MVAC with G-CSF	0
Pembrolizumab	0
Any other regimen including Paclitaxel	0
Any other chemo regimen	0
Other active systemic anti-cancer therapy [please state]	0
Palliative care only	-

Q2. Could you please provide the total number of patients with any treatment in the last three months for:

- a) Total non-small cell lung cancer (NSCLC)**
- b) BRAF+ non-small cell lung cancer (NSCLC)**

A2. In the Trust in the last 3 months there were:

- a).22 patients treated for Total non-small cell lung cancer (NSCLC)
- b).<5* Patients treated for BRAF+ non-small cell lung cancer (NSCLC)

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

A3. The number of non-small cell lung cancer (NSCLC) patients who were treated by the Trust with the drugs specified is provided in Table 2 below;

Table2

Drug	Number of Patients
Afatinib	<5*
Alectinib	<5*
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	0
Atezolizumab monotherapy	<5*
Bevacizumab	0
Brigatinib	0
Ceritinib	<5*
Crizotinib	<5*
Dacomitinib	0
Dabrafenib with Trametinib	0
Docetaxel	0
Durvalumab	0
Erlotinib	0
Gefitinib	0
Gemcitabine	0
Nintedanib with Docetaxel	0
Nivolumab	0
Osimertinib	<5*
Paclitaxel	0
Pembrolizumab chemo in combination	<5*
Pembrolizumab monotherapy	<5*
Pemetrexed with Carboplatin	7
Pemetrexed with Cisplatin	0
Pemetrexed with Cisplatin	0

** You will note that some of the numbers above have been masked and this is due to small numbers within a small geographical area.*